Association between Steroid Hormones and Insulin Resistance in Patients with Polycystic Ovary Syndrome
Abstract
Objectives: Women with Polycystic Ovary Syndrome (PCOS) are more prone to adverse outcomes, including hypertension, obesity, hyperlipidemia, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. This study examined the potential link between abnormal steroid hormone levels and insulin resistance (IR) in reproductive-aged women with PCOS.
Methods: This study involved 61 participants: a case group of 33 patients with confirmed PCOS based on Rotterdam criteria and a control group of 28 healthy individuals without PCOS. Steroid hormone levels, IR indices, metabolic markers, and demographic characteristics of participants were measured.
Results: The results showed significant differences in testosterone (P=0.018), dihydrotestosterone (DHT) (P=0.009), and androstenedione (P=0.002) levels between the two groups. Insulin levels and HOMA-IR were significantly higher in the patients (P=0.034 and 0.025, respectively). Significant correlations were found between androstenedione and insulin (P=0.021), fasting blood sugar, and homeostatic model assessment of insulin resistance (HOMA-IR) levels (P=0.001), as well as between DHT level and IR indices (P=0.03). Additionally, patients with PCOS had higher diastolic blood pressure and lower levels of T4.
Conclusion: The findings of this study showed higher androgen levels in PCOS patients and a significant correlation between DHT and androstenedione levels with IR indices in PCOS patients, which establishes a remarkable connection between hyperandrogenism and insulin resistance in PCOS.
2. Regidor PA, Mueller A, Sailer M, Gonzalez Santos F, Rizo JM, Moreno Egea F. Chronic inflammation in PCOS: the potential benefits of specialized pro-resolving lipid mediators (SPMs) in the improvement of the resolutive response. Int J Mol Sci. 2020;22(1):384.
3. Coyle CS, Prescott M, Handelsman DJ, Walters KA, Campbell RE. Chronic androgen excess in female mice does not impact luteinizing hormone pulse frequency or putative GABAergic inputs to GnRH neurons. J Neuroendocrinol. 2022;34(4):e13110.
4. Rashid U, Akbar K, Akbar H, Hajira B, Bibi S, Gul S, Afridi HA, Rashid S. Analysis OF mt-DNA encoded tRNACys gene mutations in polycyctic ovarian syndrome of disctirc abbotabad. J Xi’an Shiyou Univ Nat Sci Ed. 2022;18:325-332.
5. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015;36(5):487-525.
6. Briden L. Beyond the Label: A Patient-Centred Approach to Polycystic Ovary Syndrome.
7. Li Y, Chen C, Ma Y, Xiao J, Luo G, Li Y, Wu D. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019;228:167-75.
8. Grzywna N, Zdun S, Walczak K, Walczak P, Nemeczek S, Merkisz K, et al. Vitamin D supplementation in Polycystic ovary syndrome. J Educ Health Sport. 2023;13(2):190-5.
9. Coutinho EA, Kauffman AS. The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS). Med Sci. 2019;7(8):84.
10. Oróstica Arévalo ML, Astorga Leiva I, Plaza Parrochia F, Poblete Rivas C, Carvajal Gavilán R, et al. Metformin treatment regulates the expression of molecules involved in adiponectin and insulin signaling pathways in endometria from women with obesity-associated insulin resistance and PCOS.
11. Aziz M, Naver KV, Wissing ML, Mikkelsen AL, Nilas L, Skouby SO. Polycystic ovary syndrome: infertility, cardiovascular, metabolic and obstetrical risks, laboratory and clinical outcomes—the PICOLO study. Gynecol Endocrinol. 2012;28(4):253-8.
12. Liao B, Qiao J, Pang Y. Central regulation of PCOS: abnormal neuronal-reproductive- metabolic circuits in PCOS pathophysiology. Front Endocrinol. 2021;12:667422.
13. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544-51.
14. Wawrzkiewicz-Jałowiecka A, Kowalczyk K, Trybek P, Jarosz T, Radosz P, Setlak M, et al. In Search of New Therapeutics—Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond. Int J Mol Sci. 2020;21(19):7054.
15. Polak A, Łebkowska A, Krentowska A, Buczyńska A, Krętowski A, Kowalska I, et al. Relationships between adipocyte fatty acid-binding protein with parameters of obesity in women with polycystic ovary syndrome. Endocr Abstr. 2022;86.
16. Wawrzkiewicz-Jałowiecka A, Lalik A, Soveral G. Recent update on the molecular mechanisms of gonadal steroids action in adipose tissue. Int J Mol Sci. 2021;22(10):5226.
17. Saleh NM, Ahmed YB. Prevalence of cardiovascular risk factors among patients with polycystic ovarian syndrome (PCOS) in Erbil city. Diyala J Med. 2021;21(1):55-63.
18. Bendiab NT, Bouanane S, Ahmed FZ. Impact of polycystic ovarian syndrome (PCOS) associated with hypertension of some metabolic markers. J Hypertens. 2022;40(1):e80-.
19. Aldarazi K, Omran H, Jassim NM. Endometrial hyperplasia in asymptomatic subfertile population. J Gynecol Obstet Hum Reprod. 2022;51(4):102337.
20. Lazúrová I, Lazúrová Z, Figurová J, Ujházi S, Dravecká I, Mašlanková J, et al. Relationship between steroid hormones and metabolic profile in women with polycystic ovary syndrome. Physiol Res. 2019;68(3).
21. Yang Z, Zhou W, Zhou C, Zhou Y, Liu X, Ding G, et al. Steroid metabolome profiling of follicular fluid in normo-and hyperandrogenic women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2021;206:105806.
22. Pekcan MK, Tokmak A, Akkaya H, Pekcan G, Onur A, Kısa Ü, et al. Assessment of the Relationship Between Serum High Molecular Weight Adiponectin Hormone Levels and Insulin Resistance in Patients with Polycystic Ovary Syndrome. Horm Metab Res. 2019;51(04):261-6.
23. Li X, Zhang T, Li S, Deng Y, Wang L, Tao T, et al. Correlation between glucose metabolism and serum steroid hormones in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2020;92(4):350-7.
24. Sarwa A. Assessment of Dyslipidemia in Cases of PCOS and Its Association with Age and BMI. Int J Adv Health Sci (IJHS). 2022;9(1):21-4.
25. Khan S, Rehman S, Chughani G, Rehman M, Majid E, Amir F, et al. Association of Polycystic Ovarian Syndrome with Metabolic Disorders. J Bahria Univ Med Dent Coll. 2023;13(01):03-7.
26. Guo F, Gong Z, Fernando T, Zhang L, Zhu X, Shi Y. The lipid profiles in different characteristics of women with PCOS and the interaction between dyslipidemia and metabolic disorder states: a retrospective study in Chinese population. Front Endocrinol (Lausanne). 2022;13.
| Files | ||
| Issue | Vol 1 No 1 (2023) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/abi.v1i1.14062 | |
| Keywords | ||
| Polycystic ovary syndrome Insulin Resistance Obesity Body mass index Cholesterol Androstenedione Testosterone | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
